These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11783394)

  • 61. Artificial neural network models for the preoperative discrimination between malignant and benign adnexal masses.
    Timmerman D; Verrelst H; Bourne TH; De Moor B; Collins WP; Vergote I; Vandewalle J
    Ultrasound Obstet Gynecol; 1999 Jan; 13(1):17-25. PubMed ID: 10201082
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation.
    Menon U; Talaat A; Jeyarajah AR; Rosenthal AN; MacDonald ND; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    Br J Cancer; 1999 Jul; 80(10):1644-7. PubMed ID: 10408412
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Investigating the predictive value of RMI and ROMA indices in patients with ovarian tumors of uncertain dignity].
    Krascsenits G; Balázs B; Dudnyikova A; Purcsi K; Orosz E; Pete I
    Magy Onkol; 2016 Nov; 60(4):320-327. PubMed ID: 27898751
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparison of pelvic masses score (PMS) and Risk of Malignancy Index (RMI 3) in the evaluation of pelvic masses.
    Rossi A; Forzano L; Romanello I; Ambrosini G; Iuri V; Marchesoni D
    Eur J Gynaecol Oncol; 2014; 35(4):421-4. PubMed ID: 25118484
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
    Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study.
    Schutter EM; Sohn C; Kristen P; Möbus V; Crombach G; Kaufmann M; Caffier H; Kreienberg R; Verstraeten AA; Kenemans P
    Gynecol Oncol; 1998 Apr; 69(1):56-63. PubMed ID: 9570999
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Retrospective analysis of suspicious pelvic masses using the Pelvic Mass Index (PMI) scoring system from 2007 to 2014.
    Sinha A; Drews F; Lim K; Pugh ND
    Eur J Obstet Gynecol Reprod Biol; 2016 Jun; 201():79-84. PubMed ID: 27082132
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Validity of Cancer Antigen-125 (CA-125) and Risk of Malignancy Index (RMI) in the Diagnosis of Ovarian Cancer.
    Al-Musalhi K; Al-Kindi M; Ramadhan F; Al-Rawahi T; Al-Hatali K; Mula-Abed WA
    Oman Med J; 2015 Nov; 30(6):428-34. PubMed ID: 26675326
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Distinguishing benign and malignant pelvic masses: the value of different diagnostic methods in everyday clinical practice.
    Engelen MJ; Bongaerts AH; Sluiter WJ; de Haan HH; Bogchelman DH; Tenvergert EM; Willemse PH; van der Zee AG
    Eur J Obstet Gynecol Reprod Biol; 2008 Jan; 136(1):94-101. PubMed ID: 17118522
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Addition of parity to the risk of malignancy index score in evaluating adnexal masses.
    Yavuzcan A; Çağlar M; Özgü E; Üstün Y; Dilbaz S; Ozdemir I; Güngör T; Kumru S
    Taiwan J Obstet Gynecol; 2014 Dec; 53(4):518-22. PubMed ID: 25510694
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Preoperative clinical and radiological features of metastatic ovarian tumors.
    Bruchim I; Ben-Harim Z; Piura E; Tepper R; Fishman A
    Arch Gynecol Obstet; 2013 Sep; 288(3):615-9. PubMed ID: 23471547
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Diagnostic Value of the Risk of Malignancy Index (RMI) for Detection of Pelvic Malignancies Compared with Pathology.
    Karimi-Zarchi M; Mojaver SP; Rouhi M; Hekmatimoghaddam SH; Moghaddam RN; Yazdian-Anari P; Teimoori S
    Electron Physician; 2015 Nov; 7(7):1505-10. PubMed ID: 26767105
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative evaluation of the risk of malignancy index scoring systems (1-4) used in differential diagnosis of adnexal masses.
    Ozbay PO; Ekinci T; Caltekin MD; Yilmaz HT; Temur M; Yilmaz O; Uysal S; Demirel E; Kelekci S
    Asian Pac J Cancer Prev; 2015; 16(1):345-9. PubMed ID: 25640377
    [TBL] [Abstract][Full Text] [Related]  

  • 74. An Evaluation of the Applicability of the Risk of Malignancy Index for Adnexal Masses to Patients Seen at a Tertiary Hospital in Chandigarh, India.
    Chopra S; Vaishya R; Kaur J
    J Obstet Gynaecol India; 2015 Dec; 65(6):405-10. PubMed ID: 26664001
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Risk of malignancy index is not sensitive in detecting non-epithelial ovarian cancer and borderline ovarian tumor.
    Meray O; Türkçüoğlu I; Meydanlı MM; Kafkaslı A
    J Turk Ger Gynecol Assoc; 2010; 11(1):22-6. PubMed ID: 24591890
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparison of four malignancy risk indices in the detection of malignant ovarian masses.
    Aktürk E; Karaca RE; Alanbay I; Dede M; Karaşahin E; Yenen MC; Başer I
    J Gynecol Oncol; 2011 Sep; 22(3):177-82. PubMed ID: 21998760
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Adnexal mass vascularity assessed by 3-dimensional power Doppler: does it add to the risk of malignancy index in prediction of ovarian malignancy?: four hundred-case study.
    Mansour GM; El-Lamie IK; El-Sayed HM; Ibrahim AM; Laban M; Abou-Louz SK; Abd Allah MY; El-Mahallawi MN; El-Lamie KI; Gad-Allah M
    Int J Gynecol Cancer; 2009 Jul; 19(5):867-72. PubMed ID: 19574775
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Morphological parameters of ovarian masses and accuracy of the risk of malignancy index in diagnosing ovarian malignancy.
    Adilgereyeva AS; Abdelazim IA; Zhurabekova GA; El-Ghazaly TE
    Prz Menopauzalny; 2022 Jun; 21(2):81-91. PubMed ID: 36199743
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
    Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    BJOG; 2000 Feb; 107(2):165-9. PubMed ID: 10688498
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies.
    Kaijser J; Bourne T; Valentin L; Sayasneh A; Van Holsbeke C; Vergote I; Testa AC; Franchi D; Van Calster B; Timmerman D
    Ultrasound Obstet Gynecol; 2013 Jan; 41(1):9-20. PubMed ID: 23065859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.